The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,516

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. J., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,804

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,614

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,509

Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Deininger, M. W., Buchdunger, E., & Druker, B. J. (2004) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,269

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Russo, E., Spallarossa, A., Tasso, B., Villa, C., & Brullo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126538 · Cited by 47

Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo

Fraser, C. K., Lousberg, E. L., Kumar, R., Hughes, T. P., Diener, K. R., & Hayball, J. D. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.007 · Cited by 45

Proteomics: From Technology Developments to Biological Applications

Abu‐Farha, M., Elisma, F., Zhou, H., Tian, R., Zhou, H., Asmer, M. S., & Figeys, D. (2009) · Analytical Chemistry · doi:10.1021/ac900735j · Cited by 46

Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?

Paydaş, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.10.005 · Cited by 44

Developments of bioorthogonal handle-containing photo-crosslinkers for photoaffinity labeling

Guo, H., & Li, Z. (2017) · MedChemComm · doi:10.1039/c7md00217c · Cited by 44

Drug target deconvolution by chemical proteomics

Raida, M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.06.016 · Cited by 43

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

Hu, Z., Pan, X., Wu, F., Ma, L., Liu, D., Liu, Y., Feng, T., Meng, F., Liu, X., Jiang, Q., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006257 · Cited by 43

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?

Barton, S. R., Hawkes, E. A., Wotherspoon, A. C., & Cunningham, D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0218 · Cited by 45

New roles for B cell receptor associated kinases: when the B cell is not the target

Nguyen, P., Niesen, E., & Hallek, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0366-8 · Cited by 41

Targeting c-kit in the therapy of mast cell disorders: Current update

El‐Agamy, D. S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.06.030 · Cited by 42

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Kreutzman, A. S., Ilander, M. M., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · OncoImmunology · doi:10.4161/onci.28925 · Cited by 44

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies

Buchner, M., & Müschen, M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000048 · Cited by 42

Mechanisms of pre‐B‐cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia

Buchner, M., Swaminathan, S., Chen, Z., & Müschen, M. (2014) · Immunological Reviews · doi:10.1111/imr.12235 · Cited by 41

LCB 03-0110, a Novel Pan-Discoidin Domain Receptor/c-Src Family Tyrosine Kinase Inhibitor, Suppresses Scar Formation by Inhibiting Fibroblast and Macrophage Activation

Sun, X., Phan, T.-N., Jung, S. H., Kim, S. Y., Cho, J. U., Lee, H., Woo, S. H., Park, T. K., & Yang, B. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187328 · Cited by 41

An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B

Winter, G. E., Rix, U., Lissat, A., Stukalov, A., Müllner, M. K., Bennett, K. L., Colinge, J., Nijman, S. M. B., Kubicek, S., Kovar, H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0100 · Cited by 43

A Novel Role for Bruton's Tyrosine Kinase in Hepatocyte Growth Factor-mediated Immunoregulation of Dendritic Cells

Singhal, E., Kumar, P., & Sen, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271247 · Cited by 40

Targeted Inhibition of Kinases in Cancer Therapy

Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 39

Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution

Tse, A., & Verkhivker, G. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130203 · Cited by 38

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling

Machida, K., Eschrich, S. A., Li, J., Bai, Y., Koomen, J. M., Mayer, B. J., & Haura, E. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013470 · Cited by 38

Chronic lymphocytic leukaemia – the role of the microenvironment pathogenesis and therapy

Ramsay, A. D., & Rodriguez‐Justo, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12344 · Cited by 38

Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib

Veach, D. R., Namavari, M., Pillarsetty, N., Santos, E. B., Beresten, T., Lambek, C. L., Punzalan, B. J., Antczak, C., Smith-Jones, P. M., Djaballah, H., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070342g · Cited by 38

Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling

Levitt, J. M., Yamashita, H., Jian, W., Lerner, S. P., & Sonpavde, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0096 · Cited by 37

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

Spaargaren, M., de Rooij, M. F. M., Kater, A. P., & Eldering, E. (2014) · Oncogene · doi:10.1038/onc.2014.181 · Cited by 37

Off-Target Effects of BCR-ABL and JAK2 Inhibitors

Green, M. R., Newton, M., & Fancher, K. M. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000023 · Cited by 36

NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Almeida, J. S., Couceiro, P., López-Sejas, N., Alves, V., Růžičková, L., Tarazona, R., Solana, R., Freitas-Tavares, P., Santos-Rosa, M., & Rodrigues‐Santos, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02493 · Cited by 35

Fluorescent kinase inhibitors as probes in cancer

Usama, S. M., Zhao, B., & Burgess, K. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00017a · Cited by 35

Systems biology analysis of protein‐drug interactions

Colinge, J., Rix, U., Bennett, K. L., & Superti‐Furga, G. (2011) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201100077 · Cited by 35

Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12

McCaig, A. M., Cosimo, E., Leach, M. T. J., & Michie, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048929 · Cited by 38

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Yin, Y., Yuan, X., Gao, H., & Yang, Q. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118785 · Cited by 33

Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications

Solouki, S., August, A., & Huang, W. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.008 · Cited by 37

Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods

Piersma, S. R., Labots, M., Verheul, H. M. W., & Jiménez, C. R. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3784-7 · Cited by 32

Retrospective multicenter study on the development of peripheral lymphocytosis following second‐line dasatinib therapy for chronic myeloid leukemia

Lee, S. J., Jung, C. W., Kim, D., Lee, K., Sohn, S. K., Kwak, J., Kim, H., Kim, I. H., Park, S., & Kim, D. H. (2011) · American Journal of Hematology · doi:10.1002/ajh.21980 · Cited by 30

Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth

Ke, J., Chelvarajan, R. L., Sindhava, V. J., Robertson, D. A., Lekakis, L. J., JENNINGS, C. D., & Bondada, S. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-132 · Cited by 31

Chemical proteomics: terra incognita for novel drug target profiling

Huang, F., Zhang, B., Zhou, S., Zhao, X., Bian, C., & Wei, Y. (2012) · 癌症：英文版 · doi:10.5732/cjc.011.10377 · Cited by 30

Novel Bruton's tyrosine kinase inhibitors currently in development

Uckun, F. M., & D'Cruz (2013) · OncoTargets and Therapy · doi:10.2147/ott.s33732 · Cited by 30

The chemokine interleukin‐8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia

Hantschel, O. D., Gstöttenbauer, A., Colinge, J., Kaupe, I., Bilban, M., Burkard, T. R., Valent, P., & Superti‐Furga, G. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.07.003 · Cited by 30

4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies

de la Bellacasa, R. P., Roué, G., Balsas, P., Pérez‐Galán, P., Teixidó, J., Colomer, D., & Borrell, J. I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.018 · Cited by 29

Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing

Burchett, J. R., Dailey, J. M., Kee, S. A., Pryor, D. T., Kotha, A., Kankaria, R. A., Straus, D. B., & Ryan, J. J. (2022) · Cells · doi:10.3390/cells11193031 · Cited by 34

Chemistry-based functional proteomics for drug target deconvolution

Wang, K., Yang, T., Wu, Q., Zhao, X., Nice, E. C., & Huang, C. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.19 · Cited by 29

X‐Ray Crystal Structure of Bone Marrow Kinase in the X Chromosome: A Tec Family Kinase

Muckelbauer, J. K., Sack, J. S., Ahmed, N., Burke, J. R., Chang, C. Y., Gao, M., Tino, J. A., Xie, D., & Tebben, A. J. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01230.x · Cited by 29

Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas

Alinari, L., Quinion, C. D., & Blum, K. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.65 · Cited by 28

Chemical proteomic strategies for the discovery and development of anticancer drugs

Liu, Y., & Guo, M. (2013) · PROTEOMICS · doi:10.1002/pmic.201300261 · Cited by 28

BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers

Loboda, A. P., Adonin, L., Zvereva, S. D., Pestov, N. B., Guschin, D. Y., Korneenko, T. V., Telegina, A. V., Kondratieva, O. K., Frolova, S. E., & Barlev, N. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054982 · Cited by 32

NMDA receptors in primary afferents require phosphorylation by Src family kinases to induce substance P release in the rat spinal cord

Chen, W., Zhang, G., & Marvizón, J. C. G. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.009 · Cited by 28

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders

Walz, C., Cross, N. C. P., Etten, R. A. V., & Reiter, A. (2008) · Leukemia · doi:10.1038/leu.2008.133 · Cited by 28

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance

Kim, A., Seong, K. M., Kang, H. J., Park, S., & Lee, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5425 · Cited by 28

Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution

Saxena, C., Higgs, R. E., Zhen, Y., & Hale, J. E. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903005565 · Cited by 27

Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice

Nagy, Z., Mori, J., Ivanova, V., Mazharian, A., & Senis, Y. A. (2020) · Blood · doi:10.1182/blood.2019002848 · Cited by 27

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

Blombery, P. A., Chatzikonstantinou, T., Gerousi, M., Rosenquist, R., Gaïdano, G., Pospíšilová, Š., Roberts, A. W., Birkinshaw, R. W., Rossi, D., Scarfò, L., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02662-y · Cited by 30

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study

Kater, A. P., Spiering, M., Liu, R. D., Raa, G. D. T., Slinger, E., Tonino, S. H., Beckers, M., Daenen, S. M. G. J., Doorduijn, J. K., Lankheet, N. A. G., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.10.004 · Cited by 27

Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics

Gridling, M., Ficarro, S. B., Breitwieser, F. P., Song, L., Parapatics, K., Colinge, J., Haura, E. B., Marto, J. A., Superti‐Furga, G., Bennett, K. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0152 · Cited by 26

CD9 expression indicates a poor outcome in acute lymphoblastic leukemia

Liang, P., Miao, M., Liu, Z., Wang, H., Jiang, W., Ma, S.-Y., Li, C., & Hu, R. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170422 · Cited by 26

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Cheng, C., Woronow, D. I., Nayernama, A., Wroblewski, T., & Jones, S. C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457149 · Cited by 26

Acid Elution and One-Dimensional Shotgun Analysis on an Orbitrap Mass Spectrometer: An Application to Drug Affinity Chromatography

Fernbach, N. V., Planyavsky, M., Müller, A. C., Breitwieser, F. P., Colinge, J., Rix, U., & Bennett, K. L. (2009) · Journal of Proteome Research · doi:10.1021/pr900455x · Cited by 26

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα

Baumgärtner, C., Gleixner, K. V., Peter, B., Ferenc, V., Gruze, A., Rix, L. L. R., Bennett, K. L., Samorapoompichit, P., Lee, F. Y., Pickl, W. F., et al. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.017 · Cited by 25

Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives

Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., & Tsiftsoglou, A. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100189a · Cited by 24

IgE and Mast Cells

Oettgen, H. C., & Burton, O. T. (2015) · Advances in immunology · doi:10.1016/bs.ai.2015.03.001 · Cited by 23

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia

Creeden, J. F., Alganem, K., Imami, A. S., Henkel, N., Brunicardi, F. C., Liu, S., Shukla, R., Tomar, T., Naji, F., & McCullumsmith, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228823 · Cited by 22

Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1

Tomita, O., Iijima, K., Ishibashi, T., Osumi, T., Kobayashi, K., Okita, H., Saito, M., Mori, T., Shimizu, T., & Kiyokawa, N. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.11.017 · Cited by 22

The B-Cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology

Zhong, Y., Byrd, J. C., & Dubovsky, J. A. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.007 · Cited by 22

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation

Hadzijusufovic, E., Peter, B., Rebuzzi, L., Baumgärtner, C., Gleixner, K. V., Gruze, A., Thaiwong, T., Pickl, W. F., Yuzbasiyan‐Gurkan, V., Willmann, M., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2009.05.007 · Cited by 22

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies

Winiarska, M., Bojarczuk, K., Pyrzyńska, B., Bil, J., Kłopotowska, M., Dwojak, M., Bobrowicz, M., Miązek, N., Zapała, P., Zagożdżon, A., et al. (2014) · mAbs · doi:10.4161/mabs.32106 · Cited by 21

NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

Efremov, D. G., Wiestner, A. U., & Laurenti, L. (2012) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2012.067 · Cited by 20

Heterogeneity in the responses of human lung mast cells to stem cell factor

Lewis, A., Wan, J., Baothman, B. K., Monk, P. N., Suvarna, S. K., & Peachell, P. T. (2012) · Clinical & Experimental Allergy · doi:10.1111/cea.12045 · Cited by 20

Proteomic analysis of lymphoid and haematopoietic neoplasms: There's more than biomarker discovery

Zamò, A., & Cecconi, D. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.08.012 · Cited by 20

Quick Evaluation of Kinase Inhibitors by Surface Plasmon Resonance Using Single-Site Specifically Biotinylated Kinases

Kitagawa, D., Gouda, M., & Kirii, Y. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113506051 · Cited by 19

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

Valent, P., Órfão, A., Kubicek, S., Staber, P. B., Haferlach, T., Deininger, M. W., Kollmann, K., Lion, T., Virgolini, I. J., Winter, G. E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000536 · Cited by 23

A Fluorescence Anisotropy–Based Myt1 Kinase Binding Assay

Rohe, A., Henze, C., Erdmann, F., Sippl, W., & Schmidt, M. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2013.534 · Cited by 18

Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors

Francini, C. M., Fallacara, A. L., Artusi, R., Mennuni, L., Calgani, A., Angelucci, A., Schenone, S., & Botta, M. (2015) · ChemMedChem · doi:10.1002/cmdc.201500428 · Cited by 18

Fluorescent Visualization of Src by Using Dasatinib‐BODIPY

Vetter, M. L., Zhang, Z., Liu, S., Wang, J., Cho, H., Zhang, J., Zhang, W., Gray, N. S., & Yang, P. L. (2014) · ChemBioChem · doi:10.1002/cbic.201402010 · Cited by 18

The protein tyrosine kinase Tec regulates mast cell function

Schmidt, U., Abramova, A., Boucheron, N., Eckelhart, E., Schebesta, A., Bilić, I., Kneidinger, M., Unger, B., Hammer, M., Sibilia, M. C., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838839 · Cited by 18

Bcr-Abl tyrosine kinase inhibitors: a patent review

Desogus, A., Schenone, S., Brullo, C., Tintori, C., & Musumeci, F. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1012155 · Cited by 19

Towards Targeted Therapy of Chronic Lymphocytic Leukemia

Niemann, C. U., Jones, J. E., & Wiestner, A. U. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8051-8_12 · Cited by 18

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients

Hayette, S., Chabane, K., Michallet, M., Michallat, E., Cony‐Makhoul, P., Salesse, S., Maguer‐Satta, V., Magaud, J., & Nicolini, F. E. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.06.030 · Cited by 18

Design, Synthesis, and Evaluation of Dasatinib–Amino Acid and Dasatinib–Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors

Tiwari, R. K., Brown, A., Sadeghiani, N., Shirazi, A. N., Bolton, J., Tse, A., Verkhivker, G. M., Parang, K., & Sun, G. (2016) · ChemMedChem · doi:10.1002/cmdc.201600387 · Cited by 18

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

Rix, U., Colinge, J., Blatt, K., Gridling, M., Rix, L. L. R., Parapatics, K., Cerny‐Reiterer, S., Burkard, T. R., Jaeger, U., Melo, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077155 · Cited by 17

A magnetic bead-based protein kinase assay with dual detection techniques

Zhou, G., Sylvester, J. E., Wu, D., Veach, D. R., & Kron, S. J. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.08.034 · Cited by 17

QSAR analysis of nicotinamidic compounds and design of potential Bruton’s tyrosine kinase (Btk) inhibitors

Santos‐Garcia, L., de Assis, L. C., Silva, D. R., Ramalho, T. C., & da Cunha, E. F. F. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1070750 · Cited by 17

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Cerchione, C., Locatelli, F., & Martinelli, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632231 · Cited by 17

Protein kinase inhibitors against malignant lymphoma

D’Cruz, O. J., & Uckun, F. M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780031 · Cited by 17

Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

Seiter, K. P., Latrémouille-Viau, D., Guérin, A., Ndife, B. C., Habucky, K., Tang, D. H., Pivneva, I., Gagnon‐Sanschagrin, P., & Joseph, G. J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0772-3 · Cited by 16

Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase

Schmidt, N., Kumar, A., Korf, L., Dinh-Fricke, A. V., Abendroth, F., Koide, A., Linne, U., Rakwalska‐Bange, M., Koide, S., Essen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54901-y · Cited by 16

Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18

Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?

Valent, P. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02328.x · Cited by 16

A Miniaturized Chemical Proteomic Approach for Target Profiling of Clinical Kinase Inhibitors in Tumor Biopsies

Chamrád, I., Rix, U., Stukalov, A., Gridling, M., Parapatics, K., Müller, A. C., Altiok, S., Colinge, J., Superti‐Furga, G., Haura, E. B., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr400309p · Cited by 15

Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates

Xing, L., & Huang, A. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.24 · Cited by 14

Kinase-templated abiotic reaction

Saarbach, J., Lindberg, E., Folliet, S., Georgeon, S., Hantschel, O. D., & Winssinger, N. (2017) · Chemical Science · doi:10.1039/c7sc01416c · Cited by 14

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients

Watanabe, N., Takaku, T., Takeda, K., Shirane, S., Toyota, T., Koike, M., Noguchi, M., HIRANO, T., Fujiwara, H., & Komatsu, N. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2517-0 · Cited by 14

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma

Hollmann, C. A., Tzankov, A., Marignac, V. L. M., Baker, K., Grygorczyk, C., Grygorczyk, R., Foulkes, W. D., Nadeau, J., Dirnhofer, S., & Aloyz, R. S. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.030 · Cited by 14

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair

Nahm, W. J., & Falanga, V. (2025) · International Wound Journal · doi:10.1111/iwj.70513 · Cited by 14

Mechanosensing via a GpIIb/Src/14-3-3ζ axis critically regulates platelet migration in vascular inflammation

Kaiser, R. W. J., Anjum, A., Kammerer, L. M., Loew, Q., Akhalkatsi, A., Rossaro, D., Escaig, R., zu Senden, A. D., Raude, B., Lorenz, M., et al. (2023) · Blood · doi:10.1182/blood.2022019210 · Cited by 13

Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice

Jung, S. H., Sun, X., Ryu, W., & Yang, B. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12069 · Cited by 13

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer

Mishall, K. M., Beadnell, T. C., Kuenzi, B. M., Klimczak, D. M., Superti‐Furga, G., Rix, U., & Schweppe, R. E. (2017) · Oncotarget · doi:10.18632/oncotarget.20488 · Cited by 13

Pharmaceutical Advances and Proteomics Researches.

Khalkhal, E., Rezaei–Tavirani, M., & Rostami‐Nejad, M. (2019) · PubMed Central · doi:10.22037/ijpr.2020.112440.13758 · Cited by 13

Anchor-based classification and type-C inhibitors for tyrosine kinases

Hsu, K., Sung, T.-Y., Lin, C.-T., Chiu, Y.-Y., Hsu, J. T.-A., Hung, H., Sun, C., Barve, I. J., Chen, W., Huang, W.-C., et al. (2015) · Scientific Reports · doi:10.1038/srep10938 · Cited by 13

Critical Signal Transduction Pathways in CLL

Ghosh, A., & Kay, N. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-8051-8_10 · Cited by 12

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406)

Peter, B., Hadzijusufovic, E., Blatt, K., Gleixner, K. V., Pickl, W. F., Thaiwong, T., Yuzbasiyan‐Gurkan, V., Willmann, M., & Valent, P. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.05.004 · Cited by 12

Chapter Four – IgE and Mast Cells: The Endogenous Adjuvant

Oettgen, H. C., & Burton, O. T. (2015) · Advances in immunology · Cited by 11

Narrowing down the real targets

Daub, H. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.336 · Cited by 11

Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer

Jerin, S., Harvey, A., & Lewis, A. (2023) · Cancers · doi:10.3390/cancers15143703 · Cited by 10

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

Hantschel, O. D., Rix, U., Bürckstümmer, T., Schmidt, U., Kneidinger, M., Bennett, K. L., Kaupe, I., Ellmeier, W., Valent, P., & Superti‐Furga, G. (2007) · Blood · doi:10.1182/blood.v110.11.4542.4542 · Cited by 1

Abstract 3099: Hnd-01: a potent inhibitor of wild type mutant BTK

Zhang, J., Samatar, A. A., Tan, Y., Pi, S., Zhou, Z., Xu, Y., & Yang, D. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-3099

Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Okabe, S., Tauchi, T., & Ohyashiki, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0461 · Cited by 30

Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells.

Okabe, S., Tauchi, T., Broxmeyer, H. E., & Ohyashiki, K. (2006) · Blood · doi:10.1182/blood.v108.11.1386.1386 · Cited by 1

Dasatinib: a new step in molecular target therapy

Olivieri, A., & Manzione, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm223 · Cited by 101